Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 2002;95(Suppl 42):46–53.

Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Jacqueline de Graaf 1, Mario J Veerkamp 1, Anton F H Stalenhoef 1
PMCID: PMC1308945  PMID: 12216327

Full Text

The Full Text of this article is available as a PDF (114.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitman T. J., Godsland I. F., Farren B., Crook D., Wong H. J., Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):748–754. doi: 10.1161/01.atv.17.4.748. [DOI] [PubMed] [Google Scholar]
  2. Aouizerat B. E., Allayee H., Bodnar J., Krass K. L., Peltonen L., de Bruin T. W., Rotter J. I., Lusis A. J. Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol. 1999 Apr;10(2):113–122. doi: 10.1097/00041433-199904000-00005. [DOI] [PubMed] [Google Scholar]
  3. Arner P. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue? Curr Opin Lipidol. 1997 Apr;8(2):89–94. doi: 10.1097/00041433-199704000-00006. [DOI] [PubMed] [Google Scholar]
  4. Austin M. A., Wijsman E., Guo S. W., Krauss R. M., Brunzell J. D., Deeb S. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genet Epidemiol. 1991;8(5):287–297. doi: 10.1002/gepi.1370080502. [DOI] [PubMed] [Google Scholar]
  5. Babirak S. P., Brown B. G., Brunzell J. D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb. 1992 Oct;12(10):1176–1183. doi: 10.1161/01.atv.12.10.1176. [DOI] [PubMed] [Google Scholar]
  6. Bredie S. J., Demacker P. N., Stalenhoef A. F. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest. 1997 Oct;27(10):802–811. doi: 10.1046/j.1365-2362.1997.1850734.x. [DOI] [PubMed] [Google Scholar]
  7. Bredie S. J., Tack C. J., Smits P., Stalenhoef A. F. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler Thromb Vasc Biol. 1997 Jul;17(7):1465–1471. [PubMed] [Google Scholar]
  8. Castro Cabezas M., de Bruin T. W., de Valk H. W., Shoulders C. C., Jansen H., Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993 Jul;92(1):160–168. doi: 10.1172/JCI116544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Charlesworth J. A., Peake P. W., Campbell L. V., Pussell B. A., O'Grady S., Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Relat Metab Disord. 1998 Nov;22(11):1096–1102. doi: 10.1038/sj.ijo.0800733. [DOI] [PubMed] [Google Scholar]
  10. Cianflone K. M., Maslowska M. H., Sniderman A. D. Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. J Clin Invest. 1990 Mar;85(3):722–730. doi: 10.1172/JCI114497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cianflone K. M., Sniderman A. D., Walsh M. J., Vu H. T., Gagnon J., Rodriguez M. A. Purification and characterization of acylation stimulating protein. J Biol Chem. 1989 Jan 5;264(1):426–430. [PubMed] [Google Scholar]
  12. Cianflone K., Vu H., Walsh M., Baldo A., Sniderman A. Metabolic response of Acylation Stimulating Protein to an oral fat load. J Lipid Res. 1989 Nov;30(11):1727–1733. [PubMed] [Google Scholar]
  13. Cianflone K., Zhang X. J., Genest J., Jr, Sniderman A. Plasma acylation-stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Jul;17(7):1239–1244. [PubMed] [Google Scholar]
  14. Feingold K. R., Serio M. K., Adi S., Moser A. H., Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology. 1989 May;124(5):2336–2342. doi: 10.1210/endo-124-5-2336. [DOI] [PubMed] [Google Scholar]
  15. Ginsberg H. N., Le N. A., Goldberg I. J., Gibson J. C., Rubinstein A., Wang-Iverson P., Norum R., Brown W. V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986 Nov;78(5):1287–1295. doi: 10.1172/JCI112713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goldstein J. L., Schrott H. G., Hazzard W. R., Bierman E. L., Motulsky A. G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973 Jul;52(7):1544–1568. doi: 10.1172/JCI107332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. González-Manchón C., Martín-Requero A., Ayuso M. S., Parrilla R. Role of endogenous fatty acids in the control of hepatic gluconeogenesis. Arch Biochem Biophys. 1992 Jan;292(1):95–101. doi: 10.1016/0003-9861(92)90055-2. [DOI] [PubMed] [Google Scholar]
  18. Hauner H., Petruschke T., Russ M., Röhrig K., Eckel J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia. 1995 Jul;38(7):764–771. doi: 10.1007/s001250050350. [DOI] [PubMed] [Google Scholar]
  19. Hoffer M. J., Bredie S. J., Boomsma D. I., Reymer P. W., Kastelein J. J., de Knijff P., Demacker P. N., Stalenhoef A. F., Havekes L. M., Frants R. R. The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis. 1996 Jan 26;119(2):159–167. doi: 10.1016/0021-9150(95)05641-6. [DOI] [PubMed] [Google Scholar]
  20. Hotamisligil G. S., Arner P., Atkinson R. L., Spiegelman B. M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997 Mar;46(3):451–455. doi: 10.2337/diab.46.3.451. [DOI] [PubMed] [Google Scholar]
  21. Jacobson M. S., Yoon D. J., Frank G. R. Serum leptin is elevated out of proportion to the body mass index in adolescent females with familial combined hyperlipidemia (FCH). Clin Pediatr (Phila) 1999 Jan;38(1):49–53. doi: 10.1177/000992289903800108. [DOI] [PubMed] [Google Scholar]
  22. Juo S. H., Bredie S. J., Kiemeney L. A., Demacker P. N., Stalenhoef A. F. A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Am J Hum Genet. 1998 Aug;63(2):586–594. doi: 10.1086/301962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Karjalainen L., Pihlajamäki J., Karhapä P., Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1548–1553. doi: 10.1161/01.atv.18.10.1548. [DOI] [PubMed] [Google Scholar]
  24. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis. 1998;9(8):473–481. doi: 10.1097/00019501-199809080-00002. [DOI] [PubMed] [Google Scholar]
  25. Lewis G. F., Uffelman K. D., Szeto L. W., Weller B., Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995 Jan;95(1):158–166. doi: 10.1172/JCI117633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Meijssen S., Cabezas M. C., Twickler T. B., Jansen H., Erkelens D. W. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res. 2000 Jul;41(7):1096–1102. [PubMed] [Google Scholar]
  27. Nikkilä E. A., Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet. 1973 May 5;1(7810):954–959. doi: 10.1016/s0140-6736(73)91598-5. [DOI] [PubMed] [Google Scholar]
  28. Ong J. M., Kirchgessner T. G., Schotz M. C., Kern P. A. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J Biol Chem. 1988 Sep 15;263(26):12933–12938. [PubMed] [Google Scholar]
  29. Pajukanta P., Porkka K. V., Antikainen M., Taskinen M. R., Perola M., Murtomäki-Repo S., Ehnholm S., Nuotio I., Suurinkeroinen L., Lahdenkari A. T. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol. 1997 May;17(5):841–850. doi: 10.1161/01.atv.17.5.841. [DOI] [PubMed] [Google Scholar]
  30. Pihlajamäki J., Karjalainen L., Karhapä P., Vauhkonen I., Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):164–170. doi: 10.1161/01.atv.20.1.164. [DOI] [PubMed] [Google Scholar]
  31. Pihlajamäki J., Valve R., Karjalainen L., Karhapä P., Vauhkonen I., Laakso M. The hormone sensitive lipase gene in familial combined hyperlipidemia and insulin resistance. Eur J Clin Invest. 2001 Apr;31(4):302–308. doi: 10.1046/j.1365-2362.2001.00813.x. [DOI] [PubMed] [Google Scholar]
  32. Purnell J. Q., Kahn S. E., Schwartz R. S., Brunzell J. D. Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):567–572. doi: 10.1161/01.atv.21.4.567. [DOI] [PubMed] [Google Scholar]
  33. RANDLE P. J., GARLAND P. B., HALES C. N., NEWSHOLME E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963 Apr 13;1(7285):785–789. doi: 10.1016/s0140-6736(63)91500-9. [DOI] [PubMed] [Google Scholar]
  34. Reynisdottir S., Eriksson M., Angelin B., Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest. 1995 May;95(5):2161–2169. doi: 10.1172/JCI117905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rose H. G., Kranz P., Weinstock M., Juliano J., Haft J. I. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med. 1973 Feb;54(2):148–160. doi: 10.1016/0002-9343(73)90218-0. [DOI] [PubMed] [Google Scholar]
  36. Saleh J., Summers L. K., Cianflone K., Fielding B. A., Sniderman A. D., Frayn K. N. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res. 1998 Apr;39(4):884–891. [PubMed] [Google Scholar]
  37. Saxena U., Witte L. D., Goldberg I. J. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. J Biol Chem. 1989 Mar 15;264(8):4349–4355. [PubMed] [Google Scholar]
  38. Sniderman A. D., Castro Cabezas M., Ribalta J., Carmena R., de Bruin T. W. A., de Graaf J., Erkelens D. W., Humphries S. E., Masana L., Real J. T. A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest. 2002 Feb;32(2):71–73. doi: 10.1046/j.1365-2362.2002.00941.x. [DOI] [PubMed] [Google Scholar]
  39. Sniderman A. D., Cianflone K., Arner P., Summers L. K., Frayn K. N. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):147–151. doi: 10.1161/01.atv.18.2.147. [DOI] [PubMed] [Google Scholar]
  40. Sniderman A. D., Maslowska M., Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr Opin Lipidol. 2000 Jun;11(3):291–296. doi: 10.1097/00041433-200006000-00010. [DOI] [PubMed] [Google Scholar]
  41. Stalenhoef A. F., Malloy M. J., Kane J. P., Havel R. J. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest. 1986 Sep;78(3):722–728. doi: 10.1172/JCI112632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Taskinen M. R. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol. 1995 Jun;6(3):153–160. doi: 10.1097/00041433-199506000-00007. [DOI] [PubMed] [Google Scholar]
  43. Tchernof A., Lamarche B., Prud'Homme D., Nadeau A., Moorjani S., Labrie F., Lupien P. J., Després J. P. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 1996 Jun;19(6):629–637. doi: 10.2337/diacare.19.6.629. [DOI] [PubMed] [Google Scholar]
  44. Vakkilainen J., Porkka K. V., Nuotio I., Pajukanta P., Suurinkeroinen L., Ylitalo K., Viikari J. S., Ehnholm C., Taskinen M. R. Glucose intolerance in familial combined hyperlipidaemia. EUFAM study group. Eur J Clin Invest. 1998 Jan;28(1):24–32. doi: 10.1046/j.1365-2362.1998.00243.x. [DOI] [PubMed] [Google Scholar]
  45. Van Harmelen V., Reynisdottir S., Cianflone K., Degerman E., Hoffstedt J., Nilsell K., Sniderman A., Arner P. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem. 1999 Jun 25;274(26):18243–18251. doi: 10.1074/jbc.274.26.18243. [DOI] [PubMed] [Google Scholar]
  46. Veerkamp Mario J., de Graaf Jacqueline, Bredie Sebastian J. H., Hendriks Jan C. M., Demacker Pierre N. M., Stalenhoef Anton F. H. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):274–282. doi: 10.1161/hq0202.104059. [DOI] [PubMed] [Google Scholar]
  47. Venkatesan S., Cullen P., Pacy P., Halliday D., Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993 Jul;13(7):1110–1118. doi: 10.1161/01.atv.13.7.1110. [DOI] [PubMed] [Google Scholar]
  48. Wetsel R. A., Kildsgaard J., Zsigmond E., Liao W., Chan L. Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice. J Biol Chem. 1999 Jul 2;274(27):19429–19433. doi: 10.1074/jbc.274.27.19429. [DOI] [PubMed] [Google Scholar]
  49. Ylitalo K., Large V., Pajukanta P., Reynisdottir S., Porkka K. V., Vakkilainen J., Nuotio I., Taskinen M. R., Arner P. Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. Atherosclerosis. 2000 Dec;153(2):373–381. doi: 10.1016/s0021-9150(00)00410-x. [DOI] [PubMed] [Google Scholar]
  50. Ylitalo K., Pajukanta P., Meri S., Cantor R. M., Mero-Matikainen N., Vakkilainen J., Nuotio I., Taskinen M. R. Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2001 May;21(5):838–843. doi: 10.1161/01.atv.21.5.838. [DOI] [PubMed] [Google Scholar]
  51. Zhang X. J., Cianflone K., Genest J., Sniderman A. D. Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Eur J Clin Invest. 1998 Sep;28(9):730–739. doi: 10.1046/j.1365-2362.1998.00359.x. [DOI] [PubMed] [Google Scholar]
  52. de Graaf J., Stalenhoef A. F. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998 Jun;9(3):189–196. doi: 10.1097/00041433-199806000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES